Craif develops a cancer diagnosis algorithm by combining the microRNA database with machine learning technology.
Icaria's mission is to create a new society in which people will not lose their lives by using urine tests to provide "early, painless and accurate early diagnosis of cancer."It is known that detecting cancer early increases the survival rate 5 to 10 times and greatly improves the prognosis. However, it is not unusual for many cancers to have no subjective symptoms, and when they become aware they have progressed to a stage where treatment is impossible. The most effective way to detect cancer at an early stage that can be treated is to have regular and high-precision cancer diagnosis, but existing cancer diagnosis is painful and However, many of them are not accurate enough and are not suitable for regular diagnosis and early stage diagnosis.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 22, 2022 | Series B | — | 1 | Global Brain Corporation | — | Detail |
Nov 10, 2021 | Series Unknown | $11.34M | — | — | — | Detail |
Nov 2, 2021 | Series B | — | 1 | — | — | Detail |
Jun 17, 2020 | Series A | — | 5 | — | — | Detail |
Feb 13, 2019 | Seed | — | 3 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Global Brain Corporation | Yes | Series B |
Saisei Ventures | — | Series B |
FF APAC Scout | — | Series A |
Aflac Global Ventures | — | Series A |
ANRI | — | Series A |
Daiwa Corporate Investment | — | Series A |
Mori Trust | — | Series A |
Japan Science and Technology Agency | — | Seed |
NEDO | — | Seed |